Julian Ramírez-Bello1, Daniel Cadena-Sandoval1, José Manuel Fragoso2, Rosa Elda Barbosa-Cobos3, Mario Adán Moreno-Eutímio4, Miguel Ángel Saavedra-Salinas5, Guillermo Valencia-Pacheco6, Ricardo F López-Villanueva7, Silvia Jiménez-Morales8. 1. Unidad de Investigación en Enfermedades Metabólicas y Endócrinas, Hospital Juarez de Mexico, Mexico City, Mexico. 2. Laboratorio de Biología Molecular, Instituto Nacional de Cardiología 'Ignacio Chávez', Mexico City, Mexico. 3. Servicio de Reumatología, Hospital Juárez de Mexico, Mexico City, Mexico. 4. Unidad de Investigación en Inmunidad e Inflamación, Hospital Juárez de Mexico, Mexico City, Mexico. 5. Servicio de Reumatología, Centro Médico Nacional 'La Raza', Instituto Mexicano del Seguro Social, Mexico City, Mexico. 6. Laboratorio de Hematología, Centro de Investigación Regional 'Dr Hideyo Noguchi', Universidad Autónoma de Yucatán, Yucatan, Mexico. 7. Servicio de Reumatología, Hospital General Regional (ISSSTE), Servicio de Salud de Yucatán, Yucatán, Mexico. 8. Laboratorio de Genómica del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City, Mexico.
Abstract
BACKGROUND: Levels of circulating vascular endothelial growth factor (VEGF) (a potent endothelial-cell-specific angiogenic factor) have been correlated with disease activity in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In addition, several single nucleotide polymorphisms (SNPs), including the VEGFA -2578C/A, have been associated with RA in some populations. By contrast, the role of different VEGFA SNPs in the susceptibility to SLE has received little attention. Thus, the present study aimed to determine whether the VEGFA -2578C/A, -1154G/A and -634G/C polymorphisms confer risk or were associated with reduced risk of RA or SLE in a Mexican population. METHODS: The present study included 903 women from Mexico: 405 were patients with RA, 282 had SLE and 216 were healthy individuals. The genotypes were obtained with TaqMan probes. RESULTS: The data obtained in the present study suggest that the VEGFA -2578C/A and -634G/C polymorphisms are not risk factors for RA or SLE; however, VEGFA -1154G/A was associated with reduced risk in women with RA (odds ratio = 0.6, pc = 0.0051) but not with SLE (odds ratio = 0.7, pc = 0.13). CONCLUSIONS: The present study is the first to document an association between VEGFA -1154G/A and reduced risk in women with RA but not with SLE.
BACKGROUND: Levels of circulating vascular endothelial growth factor (VEGF) (a potent endothelial-cell-specific angiogenic factor) have been correlated with disease activity in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). In addition, several single nucleotide polymorphisms (SNPs), including the VEGFA-2578C/A, have been associated with RA in some populations. By contrast, the role of different VEGFA SNPs in the susceptibility to SLE has received little attention. Thus, the present study aimed to determine whether the VEGFA-2578C/A, -1154G/A and -634G/C polymorphisms confer risk or were associated with reduced risk of RA or SLE in a Mexican population. METHODS: The present study included 903 women from Mexico: 405 were patients with RA, 282 had SLE and 216 were healthy individuals. The genotypes were obtained with TaqMan probes. RESULTS: The data obtained in the present study suggest that the VEGFA-2578C/A and -634G/C polymorphisms are not risk factors for RA or SLE; however, VEGFA-1154G/A was associated with reduced risk in women with RA (odds ratio = 0.6, pc = 0.0051) but not with SLE (odds ratio = 0.7, pc = 0.13). CONCLUSIONS: The present study is the first to document an association between VEGFA-1154G/A and reduced risk in women with RA but not with SLE.